Abstract:BACKGROUND: A recent outbreak of SARS-CoV-2 infection occurs mainly in China, with rapidly increasing the number of cases (namely COVID-19). Abnormal liver functions are frequently present in these patients, here we aimed to clarify the clinical features of COVID-19-related liver damage to provide some references for the clinical treatment. METHODS: In this retrospective, single-center study, we included all confirmed COVID-19 cases in Shanghai Public Health Clinical Center from January 20 to January 31, 2020. The outcomes were followed up until February 19, 2020. A total of 148 cases were analyzed for clinical features, laboratory parameters (including liver function tests), medications and the length of stay. FINDINGS: Of 148 confirmed SARS-CoV-2-infected patients, 49.3% were females and 50.7% were males. The median age was 50.5 years (interquartile range, 36-64). Patients had clinical manifestations of fever (70.1%), cough (45.3%), expectoration (26.7%) at admission. 75 patients (50.7%) showed abnormal liver functions at admission, characterized by an increased of alt, ast, GGT, AKP. Patients (n = 75) who had elevated liver function index were more likely to have a moderate-high degree fever (44% vs 27.4%; p = 0.035) and significantly present in male patients (62.67% vs 38.36%; p = 0.005). The numbers of CD4+ and CD8+ T cells were significantly lower in abnormal liver function group than those in normal liver function group. There was no statistical difference in prehospital medications between normal and abnormal liver function groups, while the utilization rate of lopinavir/ritonavir after admission was significantly higher in patients with emerging liver injury than that in patients with normal liver functions. Importantly, the emerging abnormal liver functions after admission caused a prolonged length of stay. INTERPRETATION: SARS-CoV-2 may cause the liver function damage and the Lopinavir/ritonavir should be applied carefully for the treatment of COVID-19.

Pathological features of COVID-19-associated liver injury—a preliminary proteomics report based on clinical samples

Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples

A Prediction Model for COVID-19 Liver Dysfunction in Patients with Normal Hepatic Biochemical Parameters

Proteomic Analysis Identifies Prolonged Disturbances in Pathways Related to Cholesterol Metabolism and Myocardium Function in the COVID-19 Recovery Stage

Sera proteomic features of active and recovered COVID-19 patients: potential diagnostic and prognostic biomarkers

Preliminary Exploration of the Cause of Liver Disorders During Early Stages in COVID-19 Patients

Clinical Features of COVID-19-Related Liver Damage

Liver diseases in COVID-19: Etiology, treatment and prognosis.

Pathological Features of COVID-19-Associated Liver Fibros

Liver Diseases in COVID-19: Etiology, Treatment and Prognosis

Liver Injury in Patients with COVID-19: A Retrospective Study

Progress in the Clinical Features and Pathogenesis of Abnormal Liver Enzymes in Coronavirus Disease 2019

Multi-organ proteomic landscape of COVID-19 autopsies

Liver Injury in COVID-19: Detection, Pathogenesis, and Treatment

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China

COVID-19-associated liver injury: Adding fuel to the flame

Liver Histopathological Analysis of 24 Postmortem Findings of Patients With COVID-19 in China

Postmortem Tissue Proteomics Reveals the Pathogenesis of Multiorgan Injuries of COVID-19

Comprehensive analysis of the potential pathogenesis of COVID-19 infection and liver cancer

Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China

Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19